{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:17:45Z","timestamp":1790741865173,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41433-025-03909-9","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:43:35Z","timestamp":1752137015000},"page":"2534-2539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Quantifying macular atrophy in neovascular AMD using en face structural OCT imaging"],"prefix":"10.1038","volume":"39","author":[{"given":"Chiara","family":"Olivieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Tibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6412-1288","authenticated-orcid":false,"given":"Alessandro","family":"Berni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Maria","family":"Eandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Fai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-967X","authenticated-orcid":false,"given":"Pasquale","family":"Viggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Marolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Reibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-5031","authenticated-orcid":false,"given":"Enrico","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"3909_CR1","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1001\/archopht.122.4.564","volume":"122","author":"DS Friedman","year":"2004","unstructured":"Friedman DS, O\u2019Colmain BJ, Mu\u00f1oz B, Tomany SC, McCarty C, de Jong PT. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564\u201372.","journal-title":"Arch Ophthalmol"},{"key":"3909_CR2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","volume":"120","author":"FL Ferris","year":"2013","unstructured":"Ferris FL, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844\u201351.","journal-title":"Ophthalmology"},{"key":"3909_CR3","doi-asserted-by":"publisher","unstructured":"Berni A, Coletto A, Li J, Shen M, Bandello F, Reibaldi M et al. Macular atrophy in neovascular age-related macular degeneration: a systematic review and meta-analysis. Ophthalmol Retina. 2025. https:\/\/doi.org\/10.1016\/j.oret.2025.01.011.","DOI":"10.1016\/j.oret.2025.01.011"},{"key":"3909_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1159\/000519518","volume":"244","author":"C Barresi","year":"2021","unstructured":"Barresi C, Borrelli E, Fantaguzzi F, Grosso D, Sacconi R, Bandello F, Querques G. Complications associated with worse visual outcomes in patients with exudative neovascular age-related macular degeneration. Ophthalmologica. 2021;244:512\u201322.","journal-title":"Ophthalmologica"},{"key":"3909_CR5","doi-asserted-by":"crossref","unstructured":"Abdelfattah NS, Al-Sheikh M, Pitetta S, Mousa A, Sadda SR, Wykoff CC, Treat-and-Extend Age-Related Macular Degeneration Study Group. Macular atrophy in neovascular age-related macular degeneration with monthly versus treat-and-extend ranibizumab: findings from the TREX-AMD trial. Ophthalmology. 2017;124:215\u201323.","DOI":"10.1016\/j.ophtha.2016.10.002"},{"key":"3909_CR6","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ. Macular atrophy in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology. 2018;125:878\u201386.","journal-title":"Ophthalmology"},{"key":"3909_CR7","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.oret.2018.04.009","volume":"2","author":"A Domalpally","year":"2018","unstructured":"Domalpally A, Danis RP, Trane R, Blodi BA, Clemons TE, Chew EY, et al. Atrophy in neovascular age-related macular degeneration: age-related eye disease study 2 report number 15. Ophthalmol Retin. 2018;2:1021\u20137.","journal-title":"Ophthalmol Retin"},{"key":"3909_CR8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.oret.2019.06.002","volume":"3","author":"C Cheung","year":"2019","unstructured":"Cheung C, Grewal DS, Teo K, Gan A, Mohla A, Chakravarthy U, et al. The evolution of fibrosis and atrophy and their relationship with visual outcomes in Asian persons with neovascular age-related macular degeneration. Ophthalmol Retin. 2019;3:1045\u201355.","journal-title":"Ophthalmol Retin"},{"key":"3909_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ophtha.2018.07.013","volume":"126","author":"C Bailey","year":"2019","unstructured":"Bailey C, Scott LJ, Rogers CA, Reeves BC, Hamill B, Peto T, et al. Intralesional macular atrophy in anti\u2013vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN trial. Ophthalmology. 2019;126:75\u201386.","journal-title":"Ophthalmology"},{"key":"3909_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ophtha.2019.09.030","volume":"127","author":"S Gune","year":"2020","unstructured":"Gune S, Abdelfattah NS, Karamat A, Balasubramanian S, Marion KM, Morgenthien E, Sadda SR. Spectral-domain OCT\u2013based prevalence and progression of macular atrophy in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology. 2020;127:523\u201332.","journal-title":"Ophthalmology"},{"key":"3909_CR11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.oret.2022.03.010","volume":"6","author":"T Peto","year":"2022","unstructured":"Peto T, Evans RN, Reeves BC, Harding S, Madhusudhan S, Lotery A, et al. Long-term retinal morphology and functional associations in treated neovascular age-related macular degeneration. Ophthalmol Retin. 2022;6:664\u201375.","journal-title":"Ophthalmol Retin"},{"key":"3909_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/BJOPHTHALMOL-2021-319602","volume":"107","author":"M Fang","year":"2021","unstructured":"Fang M, Chanwimol K, Maram J, Datoo O'Keefe GA, Wykoff CC, Sarraf D, et al. Morphological characteristics of eyes with neovascular age-related macular degeneration and good long-term visual outcomes after anti-VEGF therapy. Br J Ophthalmol. 2021;107:399\u2013405. https:\/\/doi.org\/10.1136\/BJOPHTHALMOL-2021-319602.","journal-title":"Br J Ophthalmol"},{"key":"3909_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1167\/iovs.65.1.44","volume":"65","author":"F Ricardi","year":"2024","unstructured":"Ricardi F, Borrelli E, Boscia G, Gelormini F, Marica V, Conte F, et al. Relationship of topographic distribution of macular atrophy secondary to neovascular AMD and reading performance. Investig Opthalmol Vis Sci. 2024;65:44.","journal-title":"Investig Opthalmol Vis Sci"},{"key":"3909_CR14","doi-asserted-by":"publisher","unstructured":"Borrelli E, Olivieri C, Serafino S, Coletto A, Ricardi F, Neri G, et al. Inter-reader and inter-modality variability in macular atrophy quantification in neovascular AMD: comparison of six imaging modalities. Ophthalmol Retina. 2024. https:\/\/doi.org\/10.1016\/j.oret.2024.08.017.","DOI":"10.1016\/j.oret.2024.08.017"},{"key":"3909_CR15","doi-asserted-by":"publisher","first-page":"110117","DOI":"10.1016\/j.exer.2024.110117","volume":"248","author":"S Beqiri","year":"2024","unstructured":"Beqiri S, Herrera G, Liu J, Shen M, Berni A, El-Mulki OS, et al. Evaluating the persistence of large choroidal hypertransmission defects using SS-OCT imaging. Exp Eye Res. 2024;248:110117.","journal-title":"Exp Eye Res"},{"key":"3909_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53307-x","volume":"9","author":"E Borrelli","year":"2019","unstructured":"Borrelli E, Sacconi R, Klose G, de Sisternes L, Bandello F, Querques G, et al. Rotational three-dimensional OCTA: a notable new imaging tool to characterize type 3 macular neovascularization. Sci Rep. 2019;9:17053. https:\/\/doi.org\/10.1038\/s41598-019-53307-x.","journal-title":"Sci Rep"},{"key":"3909_CR17","doi-asserted-by":"publisher","unstructured":"Sacconi R, Borrelli E, Corbelli E, Capone L, Rabiolo A, Carnevali A et al. Quantitative changes in the ageing choriocapillaris as measured by swept source optical coherence tomography angiography. Brit J Ophthalmol. 2018. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313004.","DOI":"10.1136\/bjophthalmol-2018-313004"},{"key":"3909_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.oret.2022.01.011","volume":"6","author":"J Liu","year":"2022","unstructured":"Liu J, Laiginhas R, Corvi F, Ferris FL, Lim TH, Sadda SR, et al. Diagnosing persistent hypertransmission defects on en face OCT imaging of age-related macular degeneration. Ophthalmol Retin. 2022;6:387\u201397.","journal-title":"Ophthalmol Retin"},{"key":"3909_CR19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"3909_CR20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/bjophthalmol-2018-311849","volume":"103","author":"E Borrelli","year":"2019","unstructured":"Borrelli E, Nittala MG, Abdelfattah NS, Lei J, Hariri AH, Shi Y, et al. Comparison of short-wavelength blue-light autofluorescence and conventional blue-light autofluorescence in geographic atrophy. Br J Ophthalmol. 2019;103:610\u20136.","journal-title":"Br J Ophthalmol"},{"key":"3909_CR21","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1097\/IAE.0000000000000870","volume":"36","author":"L Kuehlewein","year":"2016","unstructured":"Kuehlewein L, Hariri AH, Ho A, Dustin L, Wolfson Y, Strauss RW, et al. Comparison of manual and semiautomated fundus autofluorescence analysis of macular atrophy in stargardt disease phenotype. Retina. 2016;36:1216\u201321.","journal-title":"Retina"},{"key":"3909_CR22","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.oret.2023.07.003","volume":"7","author":"F Corvi","year":"2023","unstructured":"Corvi F, Corradetti G, Laiginhas R, Liu J, Gregori G, Rosenfeld PJ, Sadda SR. Comparison between B-scan and en face images for incomplete and complete retinal pigment epithelium and outer retinal atrophy. Ophthalmol Retin. 2023;7:999\u20131009.","journal-title":"Ophthalmol Retin"},{"key":"3909_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ajo.2023.03.012","volume":"254","author":"J Liu","year":"2023","unstructured":"Liu J, Shen M, Laiginhas R, Herrera G, Li J, Shi Y, et al. Onset and progression of persistent choroidal hypertransmission defects in intermediate age-related macular degeneration: a novel clinical trial endpoint. Am J Ophthalmol. 2023;254:11\u201322.","journal-title":"Am J Ophthalmol"},{"key":"3909_CR24","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1038\/s41433-024-03338-0","volume":"38","author":"O Nanegrungsunk","year":"2024","unstructured":"Nanegrungsunk O, Corradetti G, Phinyo P, Choovuthayakorn J, Sadda SR. Relationship between hypertransmission defect size and progression in eyes with intermediate age-related macular degeneration. Eye. 2024;38:3488\u201394.","journal-title":"Eye"},{"key":"3909_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ajo.2021.11.001","volume":"237","author":"R Laiginhas","year":"2022","unstructured":"Laiginhas R, Shi Y, Shen M, Jiang X, Feuer W, Gregori G, Rosenfeld PJ. Persistent hypertransmission defects detected on en face swept source optical computed tomography images predict the formation of geographic atrophy in age-related macular degeneration. Am J Ophthalmol. 2022;237:58\u201370.","journal-title":"Am J Ophthalmol"},{"key":"3909_CR26","doi-asserted-by":"publisher","first-page":"9497","DOI":"10.1167\/iovs.11-8346","volume":"52","author":"UE Wolf-Schnurrbusch","year":"2011","unstructured":"Wolf-Schnurrbusch UE, Wittwer VV, Ghanem R, Niederhaeuser M, Enzmann V, Framme C, Wolf S. Blue-light versus green-light autofluorescence: lesion size of areas of geographic atrophy. Investig Opthalmol Vis Sci. 2011;52:9497\u2013502.","journal-title":"Investig Opthalmol Vis Sci"},{"key":"3909_CR27","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.oret.2024.04.017","volume":"8","author":"R Abbasgholizadeh","year":"2024","unstructured":"Abbasgholizadeh R, Bellisario G, He Y, Soylu C, Alhelaly M, Sadda SR, et al. Comparison of blue-light autofluorescence and ultrawidefield green-light autofluorescence for assessing geographic atrophy. Ophthalmol Retin. 2024;8:987\u201393. https:\/\/doi.org\/10.1016\/j.oret.2024.04.017.","journal-title":"Ophthalmol Retin"},{"key":"3909_CR28","doi-asserted-by":"publisher","first-page":"BIO121","DOI":"10.1167\/iovs.17-21764","volume":"58","author":"M Pfau","year":"2017","unstructured":"Pfau M, et al. Green-light autofluorescence versus combined blue-light autofluorescence and near-infrared reflectance imaging in geographic atrophy secondary to age-related macular degeneration. Investig Opthalmol Vis Sci. 2017;58:BIO121.","journal-title":"Investig Opthalmol Vis Sci"},{"key":"3909_CR29","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.ajo.2015.01.032","volume":"159","author":"RB Bhisitkul","year":"2015","unstructured":"Bhisitkul RB, Mendes TS, Rofagha S, Enanoria W, Boyer DS, Sadda SR, Zhang K. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol. 2015;159:915\u201324.e2.","journal-title":"Am J Ophthalmol"},{"key":"3909_CR30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.oret.2017.08.019","volume":"2","author":"G Casalino","year":"2018","unstructured":"Casalino G, Stevenson MR, Bandello F, Chakravarthy U. Tomographic biomarkers predicting progression to fibrosis in treated neovascular age-related macular degeneration: a multimodal imaging study. Ophthalmol Retin. 2018;2:451\u201361.","journal-title":"Ophthalmol Retin"},{"key":"3909_CR31","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.survophthal.2023.03.004","volume":"68","author":"I Bachmeier","year":"2023","unstructured":"Bachmeier I, Armendariz BG, Yu S, J\u00e4ger RJ, Ebneter A, Glittenberg C, et al. Fibrosis in neovascular age-related macular degeneration: a review of definitions based on clinical imaging. Surv Ophthalmol. 2023;68:835\u201348.","journal-title":"Surv Ophthalmol"},{"key":"3909_CR32","doi-asserted-by":"publisher","unstructured":"Gale RP, Airody A, Sivaprasad S, Hanson RLW, Allgar V, McKibbin M et al. Improved structure and function in early-detected second-eye neovascular age-related macular degeneration. Ophthalmol Retina. 2024. https:\/\/doi.org\/10.1016\/j.oret.2023.12.012.","DOI":"10.1016\/j.oret.2023.12.012"},{"key":"3909_CR33","doi-asserted-by":"publisher","unstructured":"Querques L, Parravano M, Borrelli E, Chiaravalloti A, Tedeschi M, Sacconi R et al. Anatomical and functional changes in neovascular AMD in remission: comparison of fibrocellular and fibrovascular phenotypes. Brit J Ophthalmol. 2020. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313685.","DOI":"10.1136\/bjophthalmol-2018-313685"},{"key":"3909_CR34","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1097\/IAE.0000000000002771","volume":"40","author":"I De Rosa","year":"2020","unstructured":"De Rosa I, Ohayon A, Semoun O, Miere A, Jung C, Capuano V, et al. Real-color versus pseudo-color imaging of fibrotic scars in exudative age-related macular degeneration. Retina. 2020;40:2277\u201384.","journal-title":"Retina"},{"key":"3909_CR35","doi-asserted-by":"publisher","first-page":"108882","DOI":"10.1016\/j.exer.2021.108882","volume":"214","author":"L Chen","year":"2022","unstructured":"Chen L, Cao D, Messinger JD, Ach T, Ferrara D, Freund KB, Curcio CA. Histology and clinical imaging lifecycle of black pigment in fibrosis secondary to neovascular age-related macular degeneration. Exp Eye Res. 2022;214:108882.","journal-title":"Exp Eye Res"},{"key":"3909_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ajo.2024.06.023","volume":"267","author":"A Berni","year":"2024","unstructured":"Berni A, Shen M, Cheng Y, Herrera G, Hiya F, Liu J, et al. The total macular burden of hyperreflective foci and the onset of persistent choroidal hypertransmission defects in intermediate AMD. Am J Ophthalmol. 2024;267:61\u201375.","journal-title":"Am J Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03909-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03909-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03909-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T03:41:02Z","timestamp":1757216462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03909-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":36,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3909"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03909-9","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EB is a member of the Eye editorial board. FB: Abbvie, Alimera, Bayer, Boehringer-Ingelheim, Fidia Sooft, Hofmann La Roche, Novartis, Ntc Pharma, Oxurion Nv, Sifi. MR: Abbvie (C), Bayer (C), Hofmann La Roche (C), Novartis (C), Zeiss (C); EB: AbbVie; Bayer; Espansione; EyePoint; Novartis; Ocular Therapeutix; Hofmann La Roche; Zeiss. Other authors: none.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}